EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea

Hee-Jin Kim iD, Heehyun Won iD, Suvin Park iD, Hui-Eon Lee iD, Haerin Cho iD, Jeong Ah Kim iD, Na-Young Jeong iD, HoJin Shin iD, Ye-Jee Kim iD, Nam-Kyong Choi iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70015 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Hee-Jin Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Convergence, Ewha Womans University, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Acute Kidney Injury, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several previous studies have identified a potential risk of acute kidney injury (AKI) associated with sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors, based on adverse event reports. However, recent European observational studies have shown conflicting results.

Objective

To evaluate the risk of AKI in patients with type 2 diabetes (T2DM) who were treated with dapagliflozin compared with sitagliptin.

Method

We conducted a retrospective cohort study on patients with T2DM who were newly prescribed dapagliflozin or sitagliptin between September 1, 2014, and June 30, 2021, using the nationwide National Health Insurance Review and Assessment (HIRA) Service database in Korea. Propensity scores were estimated using a multivariable logistic regression model, and matching was performed at a 1:1 ratio to balance the dapagliflozin and sitagliptin groups. The outcome of interest was the occurrence of AKI hospitalization 90 days post‐exposure, captured by a validated algorithm based on the International Classification of Diseases 10th Revision (ICD‐10) code: N17. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a Cox proportional hazards model.

Results

Among 94,977 dapagliflozin users matched to sitagliptin users, AKI events occurred in 132 dapagliflozin users versus 198 sitagliptin users, with incidence rates of 2.92 and 8.93 per 1000 person‐years, respectively. The risk of AKI events was 34% lower in dapagliflozin users (HR: 0.66, 95% CI: 0.53–0.83) compared with sitagliptin users. This protective effect remained consistent in sensitivity analyses.

Conclusion

Contrary to the United States Food and Drug Administration's safety warning, our findings suggest that dapagliflozin may have a protective effect against AKI in patients with T2DM. This is consistent with recent findings from European post‐marketing safety studies and may serve as supportive evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Acute Kidney InjuryBenzhydryl CompoundsGlucosidesSitagliptin PhosphateSodium-Glucose Transporter 2 InhibitorsHumansRepublic of KoreaRetrospective StudiesMaleFemalePropensity ScoreMiddle AgedAgedCohort StudiesHypoglycemic AgentsAdultHospitalization

Stichwörter der Autor:innen

acute kidney injurycohort studydipeptidyl peptidase 4 inhibitorsodium‐glucose transporter 2 inhibitors

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesSitagliptin PhosphateSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Health Convergence, Ewha Womans University, Seoul, Korea.
  • Department of Industrial Pharmaceutical Science, Ewha Womans University, Seoul, Korea.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

ORCID-Profile: Hee-Jin Kim, Heehyun Won, Suvin Park, Hui-Eon Lee, Haerin Cho, Jeong Ah Kim, Na-Young Jeong, HoJin Shin, Ye-Jee Kim, Nam-Kyong Choi

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Kim, H. J., Won, H., Park, S., Lee, H. E., Cho, H., Kim, J. A., Jeong, N. Y., Shin, H., Kim, Y. J., & Choi, N. K. (2025). Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70015

Vancouver

Kim HJ, Won H, Park S, Lee HE, Cho H, Kim JA, et al. Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70015

BibTeX
@article{Kim2025,
  author = {Kim, Hee-Jin and Won, Heehyun and Park, Suvin and Lee, Hui-Eon and Cho, Haerin and Kim, Jeong Ah and Jeong, Na-Young and Shin, HoJin and Kim, Ye-Jee and Choi, Nam-Kyong},
  title = {Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70015}
}
Kostenlos starten →